Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance

Neurology

Volumn 78, Issue 7, 2012, Pages 507-508

  Blair, Nicholas F ^a   Brew, Bruce J ^b   Halpern, Jean Pierre ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c SYDNEY ADVENTIST HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; ETIRACETAM; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SURVEILLANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84858134208     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318246d6d8     Document Type: Article

References (5)

1. Brew BJ, Davies NWS, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010;6:667- 679.
2. Sandrock A, Hotermans C, Richman S, et al. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Presented at the 63rd annual meeting of the American Academy of Neurology, April 12, 2011, Honolulu, HI.
3. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-1087.
4. Schroder A, Lee D-H, Hellwig K, Lukas C, Linker RA, Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010;67:1391-1394.
5. Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009;361: 1075-1080.